Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 049 • 2020 Pediatric Rheumatology Symposium
Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures
Danielle Fair¹, Judyann Olson ², Jan Lemke ³, Stella Protopapas ⁴, Ke Yan ⁵ and Jian Zhang ⁶, ¹Medical College of Wisconsin & Affiliated Hospitals: Children's Wisconsin, Wauwatosa, Wisconsin, ²Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, ³Children's Wisconsin, Milwaukee, Wisconsin, ⁴Riley Children’s Hospital at Indiana University, Indianapolis, Indiana, ⁵Medical College of Wisconsin, Milwaukee, Wisconsin, ⁶Medical College of Wisconsin, 53226, Wisconsin
Background/Purpose: Children with chronic diseases have higher rates of mental health issues and less favorable outcomes than the general pediatric population. Children with JIA experience…
Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Sarah Kodama¹, Deepti Gupta ², Erin Sullivan ³ and Yongdong Zhao ⁴, ¹School of Medicine, Virginia Commonwealth University, Richmond, ²Pediatric Dermatology, School of Medicine, University of Washington, Seattle, ³Seattle Children's Research Institute, Seattle, ⁴University of Washington, Seattle
Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
Abstract Number: 053 • 2020 Pediatric Rheumatology Symposium
Acceptability and Usability Testing of a Preliminary Version of the JIA Option Map, an Electronic Decision Aid for Pain Management Options in Juvenile Idiopathic Arthritis
Karine Toupin April¹, Adam Huber ², Ciaran Duffy ³, Deema Couchman ¹, Laurie Proulx ⁴, Esi Morgan ⁵, Fjolla Berbatovci ¹, Andrea Boyd ¹, Hannah Sachs ¹, Alexandra Sirois ⁶, Lucie Brosseau ³, Janice Cohen ⁷, Margaret Bisch ³, Aditi Sivakumar ¹, Marco Ragusa ¹, Tania El Hindi ⁸, Isabelle Gaboury ⁹, Linda Li ¹⁰, Elizabeth Stringer ¹¹, France Legare ¹², Sabrina Cavallo ¹³, Michele Gibbon ¹⁴, Paul Fortin ¹⁵, William Brinkman ⁵, Mark Connelly ¹⁶, Jennifer Weiss ¹⁷, Sabrina Gmuca ¹⁸, Peter Tugwell ¹⁹ and Jennifer Stinson ²⁰, ¹Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³Ottawa, Canada, ⁴Canadian Arthritis Patient Alliance, Ottawa, Canada, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Outremont, Canada, ⁷Children's Hospital of Eastern Ontario, Ottawa, Canada, ⁸Statistics Canada, Ottawa, Canada, ⁹University of Sherbrooke, Sherbrooke, Canada, ¹⁰University of British Columbia, Vancouver, Canada, ¹¹IWK Health Centre, Halifax, Canada, ¹²Laval University, Quebec City, Canada, ¹³University of Montreal, Montreal, Canada, ¹⁴Children's Hospital of Eastern Ontario RI, Ottawa, Canada, ¹⁵CHU de Quebec - Universite Laval, Quebec, Canada, ¹⁶Kansas City, ¹⁷Hackensack University Medical Center, Hackensack, ¹⁸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, ¹⁹University of Ottawa - Ottawa, Ottawa, Canada, ²⁰University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada
Background/Purpose: Although juvenile idiopathic arthritis (JIA) is one of the most common causes of chronic musculoskeletal pain among youth, families’ decision-making for pain management is…
Abstract Number: 137 • 2020 Pediatric Rheumatology Symposium
Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents
Chelsea DeCoste¹, Suzanne Ramsey ², Adam Huber ³, Bianca Lang ⁴ and Elizabeth Stringer ², ¹The Hospital for Sick Children, Toronto, Canada, ²IWK Health Centre, Halifax, Canada, ³IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁴Dalhousie University - Halifax, Halifax, Canada
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however,…
Abstract Number: 060 • 2020 Pediatric Rheumatology Symposium
Parsing Apart the Pain Experience: Exploring Treatment-Related Pain in Juvenile Idiopathic Arthritis
Yvonne Brandelli¹, Christine Chambers ², Perri Tutelman ¹, Jennifer Stinson ³, Adam Huber ⁴ and Jennifer Wilson ⁵, ¹Dalhousie University, Halifax, Nova Scotia, Canada, ²Dalhousie University & IWK Health Centre, Halifax, Nova Scotia, Canada, ³University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada, ⁴IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁵Cassie and Friends, Vancouver, British Columbia, Canada
Background/Purpose: Pain is one of the most frequently reported symptoms among children with Juvenile Idiopathic Arthritis (JIA), and in recent decades our understanding and assessment…
Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Mia Glerup¹, Ellen D Arnstad ², Veronika Rypdal ³, Suvi Peltoniemi ⁴, Kristiina Aalto ⁵, Marite Rygg ⁶, Susan Nielsen ⁷, Anders Fasth ⁸, Lillemor Berntson ⁹, Ellen Nordal ³ and Troels Herlin ¹⁰, ¹Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, ³Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ⁴Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, ⁵Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁶Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ⁷Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, ⁸Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
Abstract Number: 065 • 2020 Pediatric Rheumatology Symposium
Prosthetic Temporomandibular Joint Replacement in a Cohort of Adolescent Patients with Juvenile Idiopathic Arthritis
Jordan Jones¹ and Michael Lypka ², ¹Children's Mercy Kansas City, Kansas City, ²Children's Mercy Kansas City, Kansas City, Missouri
Background/Purpose: Temporomandibular joint (TMJ) arthritis is present in 40-96% of children with Juvenile Idiopathic Arthritis (JIA) (1). TMJ arthritis can be difficult to identify, treat,…
Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Saumya Joshi¹, Yujuan Zhang ¹ and Trevor Davis ², ¹Tufts Medical Center, Boston, Massachusetts, ²Norwell, Massachusetts
Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…
Abstract Number: 067 • 2020 Pediatric Rheumatology Symposium
Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis
Rana Masoud¹, Wajiha Jeelani ², Barbine Agbor Agbor ³, Teresa Hennon ², Brian Wrotniak ⁴ and Rabheh Abdul Aziz ², ¹Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, New York, ²Department of Pediatric Rheumatology, University at Buffalo, Oishei Children's Hospital, Buffalo, ³Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, ⁴Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, NY, USA, Buffalo
Background/Purpose: Oligo-articular juvenile idiopathic arthritis (Oligo JIA) is the most common subtype of juvenile idiopathic arthritis. Intra-articular corticosteroid (IAC) injection is a mainstay treatment of…
Abstract Number: 154 • 2020 Pediatric Rheumatology Symposium
T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis
Anna Patrick¹, Tashawna Esmond ², David Flaherty ², Thomas Brent Graham ², Susan Thompson ³ and Thomas Aune ¹, ¹Vanderbilt University Medical Center, Nashville, Tennessee, ²Vanderbilt University Medical Center, Nashville, ³Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common autoimmune arthritis in children. Polyarticular JIA and extended oligoarticular JIA both have genetic associations near genes…
Abstract Number: 003 • 2020 Pediatric Rheumatology Symposium
Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers
Julia Harris¹, Esi Morgan ², Janalee Taylor ², Tingting Qiu ³, Nancy Griffin ³, Anne Paul ⁴, C. April Bingham ⁵, Danielle Bullock ⁶, Kerry Ferraro ⁷, Mileka Gilbert ⁸, Y. Ingrid Goh ⁹, Olha Halyabar ¹⁰, Karla Jones ¹¹, Melanie Kohlheim ¹², Daniel J. Lovell ¹³, Emily Smitherman ¹⁴, Anjie Vago ⁷, Jennifer Weiss ¹⁵, Cagri Yildirim-Toruner ¹¹, Angela Young ⁷, Michelle Batthish ¹⁶, Beth Gottlieb ¹⁷, Melissa Hazen ¹⁸, Ronald Laxer ¹⁹, Tzielan Lee ²⁰, Melissa Mannion ¹⁴, Judyann Olson ²¹, Michael Shishov ²², Salma Siddique ²³, Charles Spencer ²⁴, Mary Toth ²⁵, Sheetal Vora ²⁶ and Jon Burnham ²⁷, ¹Children's Mercy Kansas City, Overland Park, ²Cincinnati Children's Hospital, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Cincinnati Children's Hospital Medical Centre, Cincinnati, ⁵Penn State Children's Hospital, Allentown, ⁶University of Minnesota, Minneapolis, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Medical University of South Carolina, Charleston, South Carolina, ⁹The Hospital for Sick Children, Toronto, Canada, ¹⁰Children's Hospital/Boston Medical Center, Boston, ¹¹Nationwide Children's Hospital, Columbus, ¹², ¹³Cincinnati, ¹⁴University of Alabama at Birmingham, Birmingham, ¹⁵Hackensack University Medical Center, Hackensack, ¹⁶McMaster University, Hamilton, Canada, ¹⁷Cohen Children's Medical Center, Lake Success, ¹⁸Boston, ¹⁹The Hospital for Sick Children and University of Toronto, Toronto, Canada, ²⁰Stanford Children's, Palo Alto, ²¹Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, ²²Phoenix Children's Hospital, Phoenix, ²³Nemours/A.I.duPont Hospital for Children, Wilmington, ²⁴Jackson, ²⁵Nemours Foundation, Orlando, ²⁶Atrium Health Levine Children's Hospital, Charlotte, ²⁷Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: In 2018, an international task force published a recommended Treat to Target (T2T) approach to JIA treatment. This treatment paradigm involves setting a treatment…
Abstract Number: 070 • 2020 Pediatric Rheumatology Symposium
The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis
Rebecca Trachtman¹, Daniel J. Lovell ², Rula Issa ¹, Stephanie Pan ¹, Karen Wilson ¹ and Karen Onel ³, ¹Icahn School of Medicine at Mount Sinai, New York, ²Cincinnati, ³Hospital for Special Surgery, New York
Background/Purpose: Polyarticular juvenile idiopathic arthritis (pJIA) is a subtype of JIA wherein more than four joints are affected with arthritis; it is characterized by unpredictable…
Abstract Number: 160 • 2020 Pediatric Rheumatology Symposium
CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis
Vincent Giacalone ¹, Alexandre Cammarata-Mouchtouris ¹, Diego Mauricio Moncada Giraldo ¹, Sreekala Shenoy ¹, Lori Ponder ¹, Talia Gergely ², Patricia Vega-Fernandez ³, Cynthia Manos ⁴, Elaine Flanagan ¹, Rabindra Tirouvanziam ¹ and Sampath Prahalad⁵, ¹emory university, atlanta, ²Emory University School of Medicine, Atlanta, ³Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Children's Healthcare of Atlanta, Atlanta, ⁵Emory + Children's Pediatric Institute, Atlanta
Background/Purpose: Rationale: Juvenile idiopathic arthritis (JIA) is an inflammatory autoimmune disorder driven by dysfunction of the joint tissue and abnormal immune responses. As deep phenotyping…
Abstract Number: 004 • 2020 Pediatric Rheumatology Symposium
Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort
Jennifer Lee¹, Simon Eng ², Brian Feldman ³, Jaime Guzman ⁴, Kiem Oen ² and Rae Yeung ³, ¹University of Toronto, Toronto, Canada, ²Toronto, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of British Columbia and BC Children's Hospital, Vancouver, Canada
Background/Purpose: PRINTO recently proposed preliminary JIA classification criteria to revise the International League of Associations for Rheumatology (ILAR) criteria. The stated aim was to obtain…
Abstract Number: 074 • 2020 Pediatric Rheumatology Symposium
Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)
Ming Min ¹, Catherine Gibson ², Mark Friswell³, Tania Crotti ⁴ and Christina Boros ⁵, ¹Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, North Adelaide, South Australia, Australia, ²Women's and Children's Health Network, North Adelaide, South Australia, Australia, ³Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, South Australia, Australia, ⁴Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia, ⁵Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, Australia
Background/Purpose: Patient outcomes and experiences are key components in the measurement of overall health outcomes in JIA and can be measured by validated PROMs and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].